Literature DB >> 21762753

Modeling the impact of RV144-like vaccines on HIV transmission.

Catherine A Hankins, John W Glasser, Robert T Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21762753      PMCID： PMC4580279          DOI： 10.1016/j.vaccine.2011.07.001

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  17 in total

1.  The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise.

Authors: 
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

2.  Combination prevention: a deeper understanding of effective HIV prevention.

Authors:  Catherine A Hankins; Barbara O de Zalduondo
Journal:  AIDS       Date:  2010-10       Impact factor: 4.177

3.  HIV vaccine research: the way forward.

Authors:  Anthony S Fauci; Margaret I Johnston; Carl W Dieffenbach; Dennis R Burton; Scott M Hammer; James A Hoxie; Malcolm Martin; Julie Overbaugh; David I Watkins; Adel Mahmoud; Warner C Greene
Journal:  Science       Date:  2008-07-25       Impact factor: 47.728

4.  Covariance analysis of censored survival data.

Authors:  N Breslow
Journal:  Biometrics       Date:  1974-03       Impact factor: 2.571

5.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  Decision making for HIV prevention and treatment scale up: bridging the gap between theory and practice.

Authors:  Sabina S Alistar; Margaret L Brandeau
Journal:  Med Decis Making       Date:  2010-12-29       Impact factor: 2.583

7.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

8.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

9.  Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.

Authors:  Peter B Gilbert; James O Berger; Donald Stablein; Stephen Becker; Max Essex; Scott M Hammer; Jerome H Kim; Victor G Degruttola
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

Review 10.  Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making?

Authors: 
Journal:  PLoS Med       Date:  2009-09-08       Impact factor: 11.069
View more
  8 in total

1.  HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.

Authors:  Joshua T Herbeck; Kathryn Peebles; Paul T Edlefsen; Morgane Rolland; James T Murphy; Geoffrey S Gottlieb; Neil Abernethy; James I Mullins; John E Mittler; Steven M Goodreau
Journal:  Vaccine       Date:  2017-12-11       Impact factor: 3.641

2.  HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation.

Authors:  Wim Delva; David P Wilson; Laith Abu-Raddad; Marelize Gorgens; David Wilson; Timothy B Hallett; Alex Welte
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

3.  HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa.

Authors:  Jeffrey W Eaton; Leigh F Johnson; Joshua A Salomon; Till Bärnighausen; Eran Bendavid; Anna Bershteyn; David E Bloom; Valentina Cambiano; Christophe Fraser; Jan A C Hontelez; Salal Humair; Daniel J Klein; Elisa F Long; Andrew N Phillips; Carel Pretorius; John Stover; Edward A Wenger; Brian G Williams; Timothy B Hallett
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

4.  The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States.

Authors:  Blythe J S Adamson; Josh J Carlson; James G Kublin; Louis P Garrison
Journal:  Vaccines (Basel)       Date:  2017-05-24

5.  The future of a partially effective HIV vaccine: assessing limitations at the population level.

Authors:  Christian Selinger; Dobromir T Dimitrov; Philip A Welkhoff; Anna Bershteyn
Journal:  Int J Public Health       Date:  2019-04-13       Impact factor: 3.380

6.  Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.

Authors:  Christian Selinger; Anna Bershteyn; Dobromir T Dimitrov; Blythe J S Adamson; Paul Revill; Timothy B Hallett; Andrew N Phillips; Linda-Gail Bekker; Helen Rees; Glenda Gray
Journal:  Vaccine       Date:  2019-03-16       Impact factor: 3.641

7.  Risk compensation after HIV-1 vaccination may accelerate viral adaptation and reduce cost-effectiveness: a modeling study.

Authors:  Kathryn Peebles; John E Mittler; Steven M Goodreau; James T Murphy; Molly C Reid; Neil Abernethy; Geoffrey S Gottlieb; Ruanne V Barnabas; Joshua T Herbeck
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

8.  Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries.

Authors:  Thomas M Harmon; Kevin A Fisher; Margaret G McGlynn; John Stover; Mitchell J Warren; Yu Teng; Arne Näveke
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.